Reply to Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data

Affiliations

• ¹ Division of Medical Oncology, Departments of Medicine and Urology, University of Washington, Seattle, Washington.
• ² Fred Hutchinson Cancer Research Center, Seattle, Washington.
• ³ Divisions of Medical Oncology and Urology, Duke University Medical Center, Duke Cancer Institute, Duke University, Durham, North Carolina.
• ⁴ Section of Hematology and Medical Oncology, Department of Medicine, Tulane Cancer Center and Tulane University School of Medicine, New Orleans, Louisiana.
• ⁵ Division of Hematology/Oncology, Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada.
• ⁶ Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York.
• ⁷ Department of Surgery, Center for Prostate Disease Research, Uniformed Services of Health Sciences, Walter Reed National Military Medical Center, Bethesda, Maryland.
• ⁸ Associated Medical Professionals, Syracuse, New York.
• ⁹ Departments of Urologic Surgery and Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee.
• ¹⁰ Department of Urology, Carolina Urologic Research Center, Myrtle Beach, South Carolina.
• ¹¹ New York Cancer and Blood Specialists, New York, New York.
• ¹² Urology Associates PC, Nashville, Tennessee.
• ¹³ Chesapeake Urology, Towson, Maryland.
• ¹⁴ Department of Medical Oncology, GU Research Network, Omaha, Nebraska.
• ¹⁵ Division of Medical Oncology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California.
• ¹⁶ Advanced Urology, Atlanta, Georgia.
• ¹⁷ Prostate Cancer Research Institute, Marina del Rey, California.
• ¹⁸ Dendreon Pharmaceuticals LLC, Seattle, Washington.
• ¹⁹ Departments of Urology and Epidemiology & Biostatistics, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.